Treatment-Related Leukemia

The majority of the published studies addressing the question of treatment-related leukemia used cohort methods of analysis in which the incidence of leukemia was measured among patients treated for primary cancer. Comparisons of the risk of leukemia have been made between patients and age- and sex-matched populations or between subsets of patients treated with different regimens. There may be bias associated with these methods,1 in that patients with Hodgkin's disease, for example, may differ from the "normal" population with respect to the risk of leukemia. The differences could include the more careful follow-up of patients with Hodgkin's disease, or more . . .